Preclinical studies have shown that the dual PI3K/mTOR inhibitor BEZ235 demonstrated antitumor activity in pancreatic cancer and glioblastoma, amongst others [10–12]. This evidence concerns the gene MTOR and familial pancreatic carcinoma.